• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Genetic Study Sheds Light on Inherited Risk of Multiple Myeloma

by | Mar 13, 2025 | Myeloma News

Source: Pharmacy Times articles Approximately 10% of patients with multiple myeloma have pathogenic germline variants, indicating a hereditary risk. Read More

A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma

by | Mar 11, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma

by | Mar 10, 2025 | Uncategorized

Source: CureToday articles Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE. Read More

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review

by | Mar 8, 2025 | Publications

Cancer Med. 2025 Mar;14(5):e70585. doi: 10.1002/cam4.70585. ABSTRACT BACKGROUND: There is a lack of clear guidance on the appropriate next choice of therapy for patients with relapsed/refractory multiple myeloma who become refractory to daratumumab, an anti-CD38...

Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma

by | Mar 8, 2025 | Myeloma News

Source: Pharmacy Times articles Pharmacists also navigate the REMS program and monitor and manage adverse effect profiles associated with bispecifics. Read More
« Older Entries
Next Entries »

Recent Content

  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration
  • (no title)
  • (no title)
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT